EUROPE IBS-C DRUG MARKET FORECAST 2020-2028

EUROPE IBS-C DRUG MARKET FORECAST 2020-2028

  • February 2020 •
  • 130 pages •
  • Report ID: 5039882 •
  • Format: PDF
KEY FINDINGS
The IBS-C drug market in Europe is predicted to register a CAGR of 9.38% during the estimated period, 2020-2028. Europe has the largest market share in the market. The demand for the market is growing, due to the highest number of patients suffering from IBS in the region.

MARKET INSIGHTS
In order to survey the Europe IBS- C drug market further, the European region is segregated into countries such as France, Poland, Italy, Belgium, Russia, the UK, Germany, and the rest of Europe that include countries like Spain and others.The Russian pharmaceutical industry is being considered by US exporters, and has huge potential, and can be distinguished into over the counter (OTC) medicines and prescription drugs.

The pharmaceutical industry accounts for 1.2% of GDP and 22.1% of Russia’s healthcare expenditure. Prescription drug sales dominated sales until 2018, which represented 62.3% of sales. In Belgium, healthcare expenditure accounted for 10% of GDP in 2016 and remained stable over the years. In order to ensure good quality and effective medicines used currently, the pharmaceutical industry is heavily regulated. In countries like Poland, the growing elderly population and the rise in the number of gastrointestinal diseases and colorectal cancer are expected to fuel the overall growth of the market. Though Poland’s pharmaceutical market lags behind most Western European nations, the market records steady growth, owing to the stability and bright outlook of the country that attracts most global pharmaceutical companies. In Spain, IBD affects 7.8% of the population and twice the number of women compared to men.

COMPETITIVE INSIGHTS
AstraZeneca, Abbott Laboratories, Ferring BV, The Menarini Group, Bama-Geve, S.L.U., etc. are some of the major companies operating in the market.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned
1. CATALENT PHARMACEUTICALS SOLUTIONS
2. ABBOTT LABORATORIES
3. NOVARTIS PHARMA AG
4. ASTELLAS PHARMACEUTICALS
5. ARDELYX, INC.
6. SYNTHETIC BIOLOGICS, INC.
7. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
8. BAMA-GEVE, SLU
9. FERRING BV
10. IRONWOOD PHARMACEUTICALS, INC.
11. SALIX PHARMACEUTICALS LTD.
12. NORGINE B.V.
13. PROMETHEUS LABORATORIES, INC.
14. ALBIREO PHARMA, INC.
15. YUHAN CORP.
16. ASTRAZENECA PLC
17. THE MENARINI GROUP
18. ONO PHARMACEUTICAL CO. LTD.
19. ACTAVIS NORDIC A/S